INDICATIONS AND USAGE
ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).
IMPORTANT SAFETY INFORMATION
WARNING: BLEEDING RISK
-Do not use ZONTIVITY in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH), or with active pathological bleeding
-Antiplatelet agents, including ZONTIVITY, increase the risk of bleeding, including ICH and fatal bleeding
CONTRAINDICATIONS:
ZONTIVITY is contraindicated in patients with a history of stroke, TIA, or ICH because of an increased risk of ICH in this population. Discontinue ZONTIVITY in patients who experience a stroke, TIA, or ICH.
ZONTIVITY is contraindicated in patients with active pathological bleeding such as ICH or peptic ulcer.